首页 > 最新文献

African Journal of Laboratory Medicine最新文献

英文 中文
Antimicrobial susceptibility of bacterial uropathogens in a South African regional hospital. 南非一家地区医院细菌性尿路病原体的抗菌药物敏感性
IF 1.1 Q3 Health Professions Pub Date : 2023-01-01 DOI: 10.4102/ajlm.v12i1.1920
Alicia Naidoo, Afsana Kajee, Nomonde R Mvelase, Khine Swe Swe-Han

Background: Urinary tract infections are common bacterial infections affecting millions worldwide. Although treatment options for urinary tract infections are well established, with ciprofloxacin long considered one of the antibiotics of choice, increasing antibiotic resistance may delay the initiation of appropriate therapy. While this increase in antimicrobial resistance has been demonstrated in multiple studies around the world, there is a dearth of information from developing countries.

Objective: This study aimed to describe the antimicrobial susceptibility patterns of commonly isolated bacterial uropathogens in a South African hospital.

Methods: Antimicrobial susceptibility data of isolates obtained from urine specimens at the RK Khan Hospital, a regional hospital in KwaZulu-Natal, South Africa, between January 2018 and December 2020 were retrieved from the hospital's laboratory information system and analysed to determine the differences in resistance rates between the most frequently isolated bacterial uropathogens.

Results: Of the 3048 bacterial urinary pathogens isolated between 2018 and 2020, Escherichia coli (1603; 53%) was the most common, followed by Klebsiella spp. (437; 14%). Both E. coli and Klebsiella spp. showed high rates of resistance to amoxicillin/clavulanic acid (29.8% and 42.3%) and ciprofloxacin (37.7% and 30.4%). Nitrofurantoin resistance was low among E. coli (6.2%) but high among Klebsiella spp. (61.3%).

Conclusion: E. coli and Klebsiella spp. in this study were highly resistant to amoxicillin/clavulanic acid and ciprofloxacin, two of the frequently prescribed oral treatment options.

What this study adds: This study highlights the importance of regular local antimicrobial resistance surveillance to inform appropriate empiric therapy.

背景:尿路感染是一种常见的细菌感染,影响着全世界数百万人。尽管尿路感染的治疗方案已经建立,环丙沙星长期以来被认为是首选抗生素之一,但抗生素耐药性的增加可能会延迟适当治疗的开始。虽然世界各地的多项研究都证明了抗菌素耐药性的增加,但发展中国家缺乏这方面的信息。目的:本研究旨在描述在南非医院常见分离的细菌尿路病原体的抗菌药物敏感性模式。方法:从南非夸祖鲁-纳塔尔省RK Khan医院的实验室信息系统中检索2018年1月至2020年12月从该医院尿液标本中获得的分离株的抗菌药物敏感性数据,并对其进行分析,以确定最常分离的尿路细菌病原体的耐药率差异。结果:在2018 - 2020年分离的3048例泌尿系统病原菌中,大肠杆菌(1603;53%)是最常见的,其次是克雷伯氏菌(437;14%)。大肠杆菌和克雷伯菌对阿莫西林/克拉维酸(29.8%和42.3%)和环丙沙星(37.7%和30.4%)的耐药率均较高。大肠杆菌对呋喃托因的耐药性较低(6.2%),而克雷伯菌对呋喃托因的耐药性较高(61.3%)。结论:本研究中大肠杆菌和克雷伯氏菌对阿莫西林/克拉维酸和环丙沙星这两种常用的口服治疗方案具有高度耐药。本研究补充说明:本研究强调了定期进行局部抗菌素耐药性监测的重要性,为适当的经验性治疗提供信息。
{"title":"Antimicrobial susceptibility of bacterial uropathogens in a South African regional hospital.","authors":"Alicia Naidoo,&nbsp;Afsana Kajee,&nbsp;Nomonde R Mvelase,&nbsp;Khine Swe Swe-Han","doi":"10.4102/ajlm.v12i1.1920","DOIUrl":"https://doi.org/10.4102/ajlm.v12i1.1920","url":null,"abstract":"<p><strong>Background: </strong>Urinary tract infections are common bacterial infections affecting millions worldwide. Although treatment options for urinary tract infections are well established, with ciprofloxacin long considered one of the antibiotics of choice, increasing antibiotic resistance may delay the initiation of appropriate therapy. While this increase in antimicrobial resistance has been demonstrated in multiple studies around the world, there is a dearth of information from developing countries.</p><p><strong>Objective: </strong>This study aimed to describe the antimicrobial susceptibility patterns of commonly isolated bacterial uropathogens in a South African hospital.</p><p><strong>Methods: </strong>Antimicrobial susceptibility data of isolates obtained from urine specimens at the RK Khan Hospital, a regional hospital in KwaZulu-Natal, South Africa, between January 2018 and December 2020 were retrieved from the hospital's laboratory information system and analysed to determine the differences in resistance rates between the most frequently isolated bacterial uropathogens.</p><p><strong>Results: </strong>Of the 3048 bacterial urinary pathogens isolated between 2018 and 2020, <i>Escherichia coli</i> (1603; 53%) was the most common, followed by <i>Klebsiella</i> spp. (437; 14%). Both <i>E. coli</i> and <i>Klebsiella</i> spp. showed high rates of resistance to amoxicillin/clavulanic acid (29.8% and 42.3%) and ciprofloxacin (37.7% and 30.4%). Nitrofurantoin resistance was low among <i>E. coli</i> (6.2%) but high among <i>Klebsiella</i> spp. (61.3%).</p><p><strong>Conclusion: </strong><i>E. coli</i> and <i>Klebsiella</i> spp. in this study were highly resistant to amoxicillin/clavulanic acid and ciprofloxacin, two of the frequently prescribed oral treatment options.</p><p><strong>What this study adds: </strong>This study highlights the importance of regular local antimicrobial resistance surveillance to inform appropriate empiric therapy.</p>","PeriodicalId":45412,"journal":{"name":"African Journal of Laboratory Medicine","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10091058/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9316870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Consequences of rpoB mutations missed by the GenoType MTBDRplus assay in a programmatic setting in South Africa. 南非程序化环境中基因型MTBDRplus检测遗漏的rpoB突变的后果
IF 1.1 Q3 Health Professions Pub Date : 2023-01-01 DOI: 10.4102/ajlm.v12i1.1975
Nomonde R Mvelase, Lindiwe P Cele, Ravesh Singh, Yeshnee Naidoo, Jennifer Giandhari, Eduan Wilkinson, Tulio de Oliveira, Khine Swe Swe-Han, Koleka P Mlisana

Background: Rifampicin resistance missed by commercial rapid molecular assays but detected by phenotypic assays may lead to discordant susceptibility results and affect patient management.

Objective: This study was conducted to evaluate the causes of rifampicin resistance missed by the GenoType MTBDRplus and its impact on the programmatic management of tuberculosis in KwaZulu-Natal, South Africa.

Methods: We analysed routine tuberculosis programme data from January 2014 to December 2014 on isolates showing rifampicin susceptibility on the GenoType MTBDRplus assay but resistance on the phenotypic agar proportion method. Whole-genome sequencing was performed on a subset of these isolates.

Results: Out of 505 patients with isoniazid mono-resistant tuberculosis on the MTBDRplus, 145 (28.7%) isolates showed both isoniazid and rifampicin resistance on the phenotypic assay. The mean time from MTBDRplus results to initiation of drug-resistant tuberculosis therapy was 93.7 days. 65.7% of the patients had received previous tuberculosis treatment. The most common mutations detected in the 36 sequenced isolates were I491F (16; 44.4%) and L452P (12; 33.3%). Among the 36 isolates, resistance to other anti-tuberculosis drugs was 69.4% for pyrazinamide, 83.3% for ethambutol, 69.4% for streptomycin, and 50% for ethionamide.

Conclusion: Missed rifampicin resistance was mostly due to the I491F mutation located outside the MTBDRplus detection area and the L452P mutation, which was not included in the initial version 2 of the MTBDRplus. This led to substantial delays in the initiation of appropriate therapy. The previous tuberculosis treatment history and the high level of resistance to other anti-tuberculosis drugs suggest an accumulation of resistance.

背景:利福平耐药被商业快速分子分析遗漏,而表型分析检测到,可能导致药敏结果不一致,影响患者的管理。目的:本研究旨在评估南非夸祖鲁-纳塔尔省MTBDRplus基因型漏诊的利福平耐药原因及其对结核病规划管理的影响。方法:我们分析了2014年1月至2014年12月的常规结核规划数据,对基因型MTBDRplus试验显示利福平敏感性,但表型琼脂比例法显示耐药性的分离株进行了分析。对这些分离物的一个子集进行了全基因组测序。结果:505例MTBDRplus异烟肼单耐药结核患者中,145株(28.7%)表型检测同时显示异烟肼和利福平耐药。从MTBDRplus结果到开始耐药结核病治疗的平均时间为93.7天。65.7%的患者既往接受过结核病治疗。36株测序菌株中检测到的最常见突变为I491F (16;44.4%)和L452P (12;33.3%)。36株结核分枝杆菌对其他抗结核药物的耐药率分别为吡嗪酰胺69.4%、乙胺丁醇83.3%、链霉素69.4%和乙硫酰胺50%。结论:遗漏的利福平耐药主要是由于位于MTBDRplus检测区域之外的I491F突变和未包含在MTBDRplus最初版本2中的L452P突变。这导致了开始适当治疗的严重延误。以往的结核病治疗史和对其他抗结核药物的高水平耐药性表明耐药性积累。
{"title":"Consequences of <i>rpoB</i> mutations missed by the GenoType MTBDR<i>plus</i> assay in a programmatic setting in South Africa.","authors":"Nomonde R Mvelase,&nbsp;Lindiwe P Cele,&nbsp;Ravesh Singh,&nbsp;Yeshnee Naidoo,&nbsp;Jennifer Giandhari,&nbsp;Eduan Wilkinson,&nbsp;Tulio de Oliveira,&nbsp;Khine Swe Swe-Han,&nbsp;Koleka P Mlisana","doi":"10.4102/ajlm.v12i1.1975","DOIUrl":"https://doi.org/10.4102/ajlm.v12i1.1975","url":null,"abstract":"<p><strong>Background: </strong>Rifampicin resistance missed by commercial rapid molecular assays but detected by phenotypic assays may lead to discordant susceptibility results and affect patient management.</p><p><strong>Objective: </strong>This study was conducted to evaluate the causes of rifampicin resistance missed by the GenoType MTBDR<i>plus</i> and its impact on the programmatic management of tuberculosis in KwaZulu-Natal, South Africa.</p><p><strong>Methods: </strong>We analysed routine tuberculosis programme data from January 2014 to December 2014 on isolates showing rifampicin susceptibility on the GenoType MTBDR<i>plus</i> assay but resistance on the phenotypic agar proportion method. Whole-genome sequencing was performed on a subset of these isolates.</p><p><strong>Results: </strong>Out of 505 patients with isoniazid mono-resistant tuberculosis on the MTBDR<i>plus</i>, 145 (28.7%) isolates showed both isoniazid and rifampicin resistance on the phenotypic assay. The mean time from MTBDR<i>plus</i> results to initiation of drug-resistant tuberculosis therapy was 93.7 days. 65.7% of the patients had received previous tuberculosis treatment. The most common mutations detected in the 36 sequenced isolates were I491F (16; 44.4%) and L452P (12; 33.3%). Among the 36 isolates, resistance to other anti-tuberculosis drugs was 69.4% for pyrazinamide, 83.3% for ethambutol, 69.4% for streptomycin, and 50% for ethionamide.</p><p><strong>Conclusion: </strong>Missed rifampicin resistance was mostly due to the I491F mutation located outside the MTBDR<i>plus</i> detection area and the L452P mutation, which was not included in the initial version 2 of the MTBDR<i>plus</i>. This led to substantial delays in the initiation of appropriate therapy. The previous tuberculosis treatment history and the high level of resistance to other anti-tuberculosis drugs suggest an accumulation of resistance.</p>","PeriodicalId":45412,"journal":{"name":"African Journal of Laboratory Medicine","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9982466/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10836669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Alternative methods for calculating percentage haemolysis of red cell concentrates in peripheral blood banks in Sri Lanka. 计算斯里兰卡外周血库中红细胞浓缩物溶血百分比的替代方法。
IF 1.1 Q3 Health Professions Pub Date : 2023-01-01 DOI: 10.4102/ajlm.v12i1.1987
Caroline A Fernando, Deklanji T Dissanayake, Uththara I Hewamana, Shyamini Rathnaweera, Wickrama A Samanthilake, Ranga Tudugala, Kithsiri B Jayasekara, Kumudu Kuruppu

Background: Haemolysis - one of the major limiting factors of red cell concentrate quality - must be measured as a quality-monitoring requirement. According to international quality standards, percentage haemolysis must be monitored in 1.0% of red cell concentrates produced monthly and maintained under 0.8%.

Objective: This study assessed three alternative methods for determining plasma haemoglobin concentration in peripheral blood banks that lack a plasma or low haemoglobin photometer - the gold-standard method - in Sri Lanka.

Methods: A standard haemolysate was prepared using an unexpired whole blood pack of normal haemoglobin concentration. A concentration series from 0.1 g/dL to 1.0 g/dL was prepared by diluting portions of standard haemolysate with saline. The alternative methods, namely visual haemoglobin colour scale, spectrophotometric calibration graph, and standard haemolysate capillary tube comparison, were designed using this concentration series and were used to test red cell concentrates received at the Quality Control Department of the National Blood Center, Sri Lanka, from February 2021 to May 2021.

Results: A strong correlation was observed between the haemoglobin photometer method and the alternative methods (R = ~0.9). Based on the linear regression model, the standard haemolysate capillary tube comparison method was the best of the three alternative methods (R 2 = 0.974).

Conclusion: All three alternative methods are recommended for use in peripheral blood banks. The standard haemolysate capillary tube comparison method was the best model.

背景:溶血是红细胞浓缩物质量的主要限制因素之一,必须作为一项质量监测要求进行测量。根据国际质量标准,每月生产的红细胞浓缩液的溶血百分比必须监测在1.0%,并保持在0.8%以下。目的:本研究评估了在斯里兰卡缺乏血浆或低血红蛋白光度计(金标准方法)的外周血库中测定血浆血红蛋白浓度的三种替代方法。方法:用正常血红蛋白浓度的未过期全血包制备标准溶血液。用生理盐水稀释部分标准溶血液,得到从0.1 g/dL到1.0 g/dL的浓度系列。使用该浓度系列设计了替代方法,即目视血红蛋白颜色标度、分光光度校准图和标准溶血液毛细管比较,并用于测试2021年2月至2021年5月期间斯里兰卡国家血液中心质量控制部收到的红细胞浓缩物。结果:血红蛋白光度计法与其他方法有很强的相关性(R = ~0.9)。基于线性回归模型,标准溶血液毛细管比较法在3种方法中效果最好(r2 = 0.974)。结论:三种方法均可用于外周血库。标准溶血液毛细管比较法为最佳模型。
{"title":"Alternative methods for calculating percentage haemolysis of red cell concentrates in peripheral blood banks in Sri Lanka.","authors":"Caroline A Fernando,&nbsp;Deklanji T Dissanayake,&nbsp;Uththara I Hewamana,&nbsp;Shyamini Rathnaweera,&nbsp;Wickrama A Samanthilake,&nbsp;Ranga Tudugala,&nbsp;Kithsiri B Jayasekara,&nbsp;Kumudu Kuruppu","doi":"10.4102/ajlm.v12i1.1987","DOIUrl":"https://doi.org/10.4102/ajlm.v12i1.1987","url":null,"abstract":"<p><strong>Background: </strong>Haemolysis - one of the major limiting factors of red cell concentrate quality - must be measured as a quality-monitoring requirement. According to international quality standards, percentage haemolysis must be monitored in 1.0% of red cell concentrates produced monthly and maintained under 0.8%.</p><p><strong>Objective: </strong>This study assessed three alternative methods for determining plasma haemoglobin concentration in peripheral blood banks that lack a plasma or low haemoglobin photometer - the gold-standard method - in Sri Lanka.</p><p><strong>Methods: </strong>A standard haemolysate was prepared using an unexpired whole blood pack of normal haemoglobin concentration. A concentration series from 0.1 g/dL to 1.0 g/dL was prepared by diluting portions of standard haemolysate with saline. The alternative methods, namely visual haemoglobin colour scale, spectrophotometric calibration graph, and standard haemolysate capillary tube comparison, were designed using this concentration series and were used to test red cell concentrates received at the Quality Control Department of the National Blood Center, Sri Lanka, from February 2021 to May 2021.</p><p><strong>Results: </strong>A strong correlation was observed between the haemoglobin photometer method and the alternative methods (<i>R</i> = ~0.9). Based on the linear regression model, the standard haemolysate capillary tube comparison method was the best of the three alternative methods (<i>R</i> <sup>2</sup> = 0.974).</p><p><strong>Conclusion: </strong>All three alternative methods are recommended for use in peripheral blood banks. The standard haemolysate capillary tube comparison method was the best model.</p>","PeriodicalId":45412,"journal":{"name":"African Journal of Laboratory Medicine","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9982517/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10836672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum: Formulation of phage cocktails and evaluation of their interaction with antibiotics in inhibiting carbapenemase-producing Klebsiella pneumoniae in vitro in Kenya. 勘误:噬菌体鸡尾酒的配方及其与抗生素在肯尼亚体外抑制产碳青霉烯酶肺炎克雷伯菌相互作用的评价。
IF 1.1 Q3 Health Professions Pub Date : 2023-01-01 DOI: 10.4102/ajlm.v12i1.2028
Noutin F Michodigni, Atunga Nyachieo, Juliah K Akhwale, Gabriel Magoma, Abdoul-Salam Ouédraogo, Andrew N Kimang'a

[This corrects the article DOI: 10.4102/ajlm.v11i1.1803.].

[这更正了文章DOI: 10.4102/ajlm.v11i1.1803.]。
{"title":"Corrigendum: Formulation of phage cocktails and evaluation of their interaction with antibiotics in inhibiting carbapenemase-producing <i>Klebsiella pneumoniae</i> in vitro in Kenya.","authors":"Noutin F Michodigni,&nbsp;Atunga Nyachieo,&nbsp;Juliah K Akhwale,&nbsp;Gabriel Magoma,&nbsp;Abdoul-Salam Ouédraogo,&nbsp;Andrew N Kimang'a","doi":"10.4102/ajlm.v12i1.2028","DOIUrl":"https://doi.org/10.4102/ajlm.v12i1.2028","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.4102/ajlm.v11i1.1803.].</p>","PeriodicalId":45412,"journal":{"name":"African Journal of Laboratory Medicine","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10244820/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9601423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Building clinical pharmacology laboratory capacity in low- and middle-income countries: Experience from Uganda. 在低收入和中等收入国家建立临床药理学实验室能力:来自乌干达的经验。
IF 1.1 Q3 Health Professions Pub Date : 2023-01-01 DOI: 10.4102/ajlm.v12i1.1956
Denis Omali, Allan Buzibye, Richard Kwizera, Pauline Byakika-Kibwika, Rhoda Namakula, Joshua Matovu, Olive Mbabazi, Emmanuel Mande, Christine Sekaggya-Wiltshire, Damalie Nakanjako, Ursula Gutteck, Keith McAdam, Philippa Easterbrook, Andrew Kambugu, Jan Fehr, Barbara Castelnuovo, Yukari C Manabe, Mohammed Lamorde, Daniel Mueller, Concepta Merry

Background: Research and clinical use of clinical pharmacology laboratories are limited in low- and middle-income countries. We describe our experience in building and sustaining laboratory capacity for clinical pharmacology at the Infectious Diseases Institute, Kampala, Uganda.

Intervention: Existing laboratory infrastructure was repurposed, and new equipment was acquired. Laboratory personnel were hired and trained to optimise, validate, and develop in-house methods for testing antiretroviral, anti-tuberculosis and other drugs, including 10 high-performance liquid chromatography methods and four mass spectrometry methods. We reviewed all research collaborations and projects for which samples were assayed in the laboratory from January 2006 to November 2020. We assessed laboratory staff mentorship from collaborative relationships and the contribution of research projects towards human resource development, assay development, and equipment and maintenance costs. We further assessed the quality of testing and use of the laboratory for research and clinical care.

Lessons learnt: Fourteen years post inception, the clinical pharmacology laboratory had contributed significantly to the overall research output at the institute by supporting 26 pharmacokinetic studies. The laboratory has actively participated in an international external quality assurance programme for the last four years. For clinical care, a therapeutic drug monitoring service is accessible to patients living with HIV at the Adult Infectious Diseases clinic in Kampala, Uganda.

Recommendations: Driven primarily by research projects, clinical pharmacology laboratory capacity was successfully established in Uganda, resulting in sustained research output and clinical support. Strategies implemented in building capacity for this laboratory may guide similar processes in other low- and middle-income countries.

背景:临床药理学实验室的研究和临床使用在低收入和中等收入国家是有限的。我们将介绍我们在乌干达坎帕拉传染病研究所建设和维持临床药理学实验室能力方面的经验。干预措施:改造现有实验室基础设施,购置新设备。聘用和培训了实验室人员,以优化、验证和开发检测抗逆转录病毒、抗结核病和其他药物的内部方法,包括10种高效液相色谱法和4种质谱法。我们回顾了2006年1月至2020年11月在实验室检测样本的所有研究合作和项目。我们从合作关系和研究项目对人力资源开发、分析开发、设备和维护成本的贡献中评估了实验室工作人员的指导。我们进一步评估了实验室在研究和临床护理中的检测质量和使用情况。经验教训:成立14年后,临床药理学实验室通过支持26项药代动力学研究,对研究所的整体研究成果做出了重大贡献。过去四年,化验所积极参与一项国际外部质素保证计划。在临床护理方面,乌干达坎帕拉成人传染病诊所向艾滋病毒感染者提供治疗性药物监测服务。建议:主要在研究项目的推动下,乌干达成功建立了临床药理学实验室能力,从而产生了持续的研究产出和临床支持。为该实验室能力建设实施的战略可以指导其他低收入和中等收入国家的类似进程。
{"title":"Building clinical pharmacology laboratory capacity in low- and middle-income countries: Experience from Uganda.","authors":"Denis Omali,&nbsp;Allan Buzibye,&nbsp;Richard Kwizera,&nbsp;Pauline Byakika-Kibwika,&nbsp;Rhoda Namakula,&nbsp;Joshua Matovu,&nbsp;Olive Mbabazi,&nbsp;Emmanuel Mande,&nbsp;Christine Sekaggya-Wiltshire,&nbsp;Damalie Nakanjako,&nbsp;Ursula Gutteck,&nbsp;Keith McAdam,&nbsp;Philippa Easterbrook,&nbsp;Andrew Kambugu,&nbsp;Jan Fehr,&nbsp;Barbara Castelnuovo,&nbsp;Yukari C Manabe,&nbsp;Mohammed Lamorde,&nbsp;Daniel Mueller,&nbsp;Concepta Merry","doi":"10.4102/ajlm.v12i1.1956","DOIUrl":"https://doi.org/10.4102/ajlm.v12i1.1956","url":null,"abstract":"<p><strong>Background: </strong>Research and clinical use of clinical pharmacology laboratories are limited in low- and middle-income countries. We describe our experience in building and sustaining laboratory capacity for clinical pharmacology at the Infectious Diseases Institute, Kampala, Uganda.</p><p><strong>Intervention: </strong>Existing laboratory infrastructure was repurposed, and new equipment was acquired. Laboratory personnel were hired and trained to optimise, validate, and develop in-house methods for testing antiretroviral, anti-tuberculosis and other drugs, including 10 high-performance liquid chromatography methods and four mass spectrometry methods. We reviewed all research collaborations and projects for which samples were assayed in the laboratory from January 2006 to November 2020. We assessed laboratory staff mentorship from collaborative relationships and the contribution of research projects towards human resource development, assay development, and equipment and maintenance costs. We further assessed the quality of testing and use of the laboratory for research and clinical care.</p><p><strong>Lessons learnt: </strong>Fourteen years post inception, the clinical pharmacology laboratory had contributed significantly to the overall research output at the institute by supporting 26 pharmacokinetic studies. The laboratory has actively participated in an international external quality assurance programme for the last four years. For clinical care, a therapeutic drug monitoring service is accessible to patients living with HIV at the Adult Infectious Diseases clinic in Kampala, Uganda.</p><p><strong>Recommendations: </strong>Driven primarily by research projects, clinical pharmacology laboratory capacity was successfully established in Uganda, resulting in sustained research output and clinical support. Strategies implemented in building capacity for this laboratory may guide similar processes in other low- and middle-income countries.</p>","PeriodicalId":45412,"journal":{"name":"African Journal of Laboratory Medicine","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9982508/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9400527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An assessment of the laboratory network in Ghana: A national-level ATLAS survey (2019-2020). 加纳实验室网络评估:一项国家级ATLAS调查(2019-2020)。
IF 1.1 Q3 Health Professions Pub Date : 2023-01-01 DOI: 10.4102/ajlm.v12i1.1844
Emma E Kploanyi, Joseph Kenu, Benedicta K Atsu, David A Opare, Franklin Asiedu-Bekoe, Lee F Schroeder, David W Dowdy, Alfred E Yawson, Ernest Kenu

Background: Integrated health systems with strong laboratory networks are critical in improving public health. The current study assessed the laboratory network in Ghana and its functionality using the Assessment Tool for Laboratory Services (ATLAS).

Intervention: A national-level laboratory network survey was conducted among stakeholders of the Ghanaian laboratory network in Accra. Face-to-face interviews were conducted from December 2019 to January 2020, with follow-up phone interviews between June and July 2020. Also, we reviewed supporting documents provided by stakeholders for supplementary information and transcribed these to identify themes. Where possible, we completed the Laboratory Network scorecard using data obtained from the ATLAS.

Lessons learnt: The Laboratory Network (LABNET) scorecard assessment was a valuable addition to the ATLAS survey as it quantified the functionality of the laboratory network and its overall advancement toward achieving International Health Regulations (2005) and Global Health Security Agenda targets. Two significant challenges indicated by respondents were laboratory financing and delayed implementation of the Ghana National Health Laboratory Policy.

Recommendations: Stakeholders recommended a review of the country's funding landscape, such as funding laboratory services from the country's internally generated funds. Also, they recommended laboratory policy implementation to ensure adequate laboratory workforce and standards.

背景:具有强大实验室网络的综合卫生系统对改善公共卫生至关重要。目前的研究使用实验室服务评估工具(ATLAS)评估了加纳的实验室网络及其功能。干预措施:在阿克拉的加纳实验室网络的利益相关者中进行了国家级实验室网络调查。面对面访谈于2019年12月至2020年1月进行,后续电话访谈于2020年6月至7月进行。此外,我们审查了利益相关者提供的补充信息的支持文件,并将其转录以确定主题。在可能的情况下,我们使用ATLAS获得的数据完成了实验室网络记分卡。经验教训:实验室网络计分卡评估是ATLAS调查的宝贵补充,因为它量化了实验室网络的功能及其在实现《国际卫生条例(2005)》和全球卫生安全议程目标方面的总体进展。答复者指出的两项重大挑战是实验室资金筹措和加纳国家卫生实验室政策的延迟执行。建议:利益攸关方建议审查该国的供资情况,例如从该国内部产生的资金中资助实验室服务。此外,他们建议实施实验室政策,以确保足够的实验室工作人员和标准。
{"title":"An assessment of the laboratory network in Ghana: A national-level ATLAS survey (2019-2020).","authors":"Emma E Kploanyi,&nbsp;Joseph Kenu,&nbsp;Benedicta K Atsu,&nbsp;David A Opare,&nbsp;Franklin Asiedu-Bekoe,&nbsp;Lee F Schroeder,&nbsp;David W Dowdy,&nbsp;Alfred E Yawson,&nbsp;Ernest Kenu","doi":"10.4102/ajlm.v12i1.1844","DOIUrl":"https://doi.org/10.4102/ajlm.v12i1.1844","url":null,"abstract":"<p><strong>Background: </strong>Integrated health systems with strong laboratory networks are critical in improving public health. The current study assessed the laboratory network in Ghana and its functionality using the Assessment Tool for Laboratory Services (ATLAS).</p><p><strong>Intervention: </strong>A national-level laboratory network survey was conducted among stakeholders of the Ghanaian laboratory network in Accra. Face-to-face interviews were conducted from December 2019 to January 2020, with follow-up phone interviews between June and July 2020. Also, we reviewed supporting documents provided by stakeholders for supplementary information and transcribed these to identify themes. Where possible, we completed the Laboratory Network scorecard using data obtained from the ATLAS.</p><p><strong>Lessons learnt: </strong>The Laboratory Network (LABNET) scorecard assessment was a valuable addition to the ATLAS survey as it quantified the functionality of the laboratory network and its overall advancement toward achieving International Health Regulations (2005) and Global Health Security Agenda targets. Two significant challenges indicated by respondents were laboratory financing and delayed implementation of the Ghana National Health Laboratory Policy.</p><p><strong>Recommendations: </strong>Stakeholders recommended a review of the country's funding landscape, such as funding laboratory services from the country's internally generated funds. Also, they recommended laboratory policy implementation to ensure adequate laboratory workforce and standards.</p>","PeriodicalId":45412,"journal":{"name":"African Journal of Laboratory Medicine","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9982496/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10836668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of delayed sample draw after blood collection for haemoglobin test in South Korea. 韩国血红蛋白测试采血后延迟取样的影响。
IF 1.1 Q3 Health Professions Pub Date : 2023-01-01 DOI: 10.4102/ajlm.v12i1.2008
Hyerim Kim, Jongmin Kim

Between April and May 2022, 10 healthy adult non-patients were recruited from Pusan National University Hospital. Venous blood drawn into a syringe was transferred into test tubes with a zero-to-45-minute delay. The transfer was done sequentially in two positions with the syringe and the needle adaptor end (1) heading downwards and (2) heading upwards. Haemoglobin levels gradually increased over time in position 1 transfer while they gradually decreased in position 2. Therefore, blood must be transferred quickly from a syringe to a tube for reliable test results.

What this study adds: Our findings confirm that delays between blood collection and transfer can affect haemoglobin levels.

在2022年4月至5月期间,从釜山国立大学医院招募了10名健康成人非患者。注入注射器的静脉血在0到45分钟的延迟后被转移到试管中。在两个位置依次进行转移,注射器和针头适配器端(1)向下,(2)向上。血红蛋白水平随着时间的推移在1位转移中逐渐增加,而在2位转移中逐渐降低。因此,为了获得可靠的检测结果,血液必须迅速从注射器转移到试管中。这项研究补充说:我们的研究结果证实,血液采集和输送之间的延迟会影响血红蛋白水平。
{"title":"Effect of delayed sample draw after blood collection for haemoglobin test in South Korea.","authors":"Hyerim Kim,&nbsp;Jongmin Kim","doi":"10.4102/ajlm.v12i1.2008","DOIUrl":"https://doi.org/10.4102/ajlm.v12i1.2008","url":null,"abstract":"<p><p>Between April and May 2022, 10 healthy adult non-patients were recruited from Pusan National University Hospital. Venous blood drawn into a syringe was transferred into test tubes with a zero-to-45-minute delay. The transfer was done sequentially in two positions with the syringe and the needle adaptor end (1) heading downwards and (2) heading upwards. Haemoglobin levels gradually increased over time in position 1 transfer while they gradually decreased in position 2. Therefore, blood must be transferred quickly from a syringe to a tube for reliable test results.</p><p><strong>What this study adds: </strong>Our findings confirm that delays between blood collection and transfer can affect haemoglobin levels.</p>","PeriodicalId":45412,"journal":{"name":"African Journal of Laboratory Medicine","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10091068/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9371288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Table of Contents Vol 11, No 1 目录第11卷第1号
IF 1.1 Q3 Health Professions Pub Date : 2022-12-31 DOI: 10.4102/ajlm.v11i1.2143
Editorial Office
No abstract available.
没有可用的摘要。
{"title":"Table of Contents Vol 11, No 1","authors":"Editorial Office","doi":"10.4102/ajlm.v11i1.2143","DOIUrl":"https://doi.org/10.4102/ajlm.v11i1.2143","url":null,"abstract":"No abstract available.","PeriodicalId":45412,"journal":{"name":"African Journal of Laboratory Medicine","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2022-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46452353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Malaria an opportunistic infection in HIV/AIDS patients? - A Nigerian experience. 疟疾是艾滋病毒/艾滋病患者的机会性感染吗?- 尼日利亚的经验。
IF 1 Q4 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2022-11-24 eCollection Date: 2022-01-01 DOI: 10.4102/ajlm.v11i1.1842
Joseph N Enuma, Felix O Sanni, Malau B Matur, Njab E Jean, Tosan Erhabor, Iheukwumere I Egbulefu

Background: HIV and malaria interact at the level of the host's susceptibility to infection, but little is known about the effect of HIV on malaria infection in Nigeria.

Objective: This study estimated the prevalence of malaria parasitaemia and its relationship with HIV immunodeficiency.

Methods: This cross-sectional study was conducted in two hospitals in Abuja, Nigeria between October 2012 and March 2013 among 600 respondents, comprising 200 HIV-negative controls, 200 HIV-positive patients on antiretroviral therapy (ART), and 200 HIV-positive patients not on ART. Malaria parasites, malaria density and absolute CD4 counts were carried out on all three groups. Participants with CD4 counts below 350 cells/mm3 were considered immunocompromised and likely to develop opportunistic infections.

Results: Most study participants were aged 21-40 years (65.2%). The mean CD4 counts of HIV-positive patients not on ART (300 ± 211 cells/mm3) and those on ART (354 cells/mm3) were significantly lower than among controls (834 cells/mm3) (p < 0.001). Malaria prevalence was not statistically different between the controls (44.5%), patients on ART (40.5%), and those not on ART (39.5%) (p = 0.562). Compared to 7% immunodeficiency among controls, 56% of patients on ART and 65.5% of those not on ART had a CD4 count < 350 cells/mm3 (p < 0.001). The prevalence of malaria parasitaemia among immunodeficient individuals (42.4%) was similar to prevalence among those with CD4 counts > 350 cells/mm3 (40.8%; p = 0.695).

Conclusion: These findings suggest that malaria parasitaemia is not an opportunistic infection among HIV-positive individuals in Nigeria.

背景:艾滋病毒和疟疾在宿主的感染易感性水平上相互影响,但在尼日利亚,人们对艾滋病毒对疟疾感染的影响知之甚少:本研究估计了疟疾寄生虫血症的发病率及其与 HIV 免疫缺陷的关系:这项横断面研究于 2012 年 10 月至 2013 年 3 月在尼日利亚阿布贾的两家医院进行,共有 600 名受访者,其中包括 200 名 HIV 阴性对照者、200 名接受抗逆转录病毒疗法 (ART) 的 HIV 阳性患者和 200 名未接受抗逆转录病毒疗法的 HIV 阳性患者。对所有三组受访者进行了疟疾寄生虫、疟疾密度和 CD4 绝对计数检测。CD4 细胞计数低于 350 cells/mm3 的参与者被视为免疫力低下,可能会出现机会性感染:大多数研究参与者的年龄在 21-40 岁之间(65.2%)。未接受抗逆转录病毒疗法的艾滋病毒阳性患者的平均 CD4 细胞数(300 ± 211 cells/mm3)和接受抗逆转录病毒疗法的患者的平均 CD4 细胞数(354 cells/mm3)明显低于对照组(834 cells/mm3)(p < 0.001)。疟疾流行率在对照组(44.5%)、接受抗逆转录病毒疗法的患者(40.5%)和未接受抗逆转录病毒疗法的患者(39.5%)之间没有统计学差异(p = 0.562)。与对照组 7% 的免疫缺陷率相比,56% 接受抗逆转录病毒疗法的患者和 65.5% 未接受抗逆转录病毒疗法的患者的 CD4 细胞计数小于 350 cells/mm3(p < 0.001)。免疫缺陷者中疟疾寄生虫血症的流行率(42.4%)与 CD4 细胞计数大于 350 cells/mm3 者的流行率(40.8%;p = 0.695)相似:这些研究结果表明,疟疾寄生虫病并不是尼日利亚艾滋病毒抗体阳性者的机会性感染。
{"title":"Malaria an opportunistic infection in HIV/AIDS patients? - A Nigerian experience.","authors":"Joseph N Enuma, Felix O Sanni, Malau B Matur, Njab E Jean, Tosan Erhabor, Iheukwumere I Egbulefu","doi":"10.4102/ajlm.v11i1.1842","DOIUrl":"10.4102/ajlm.v11i1.1842","url":null,"abstract":"<p><strong>Background: </strong>HIV and malaria interact at the level of the host's susceptibility to infection, but little is known about the effect of HIV on malaria infection in Nigeria.</p><p><strong>Objective: </strong>This study estimated the prevalence of malaria parasitaemia and its relationship with HIV immunodeficiency.</p><p><strong>Methods: </strong>This cross-sectional study was conducted in two hospitals in Abuja, Nigeria between October 2012 and March 2013 among 600 respondents, comprising 200 HIV-negative controls, 200 HIV-positive patients on antiretroviral therapy (ART), and 200 HIV-positive patients not on ART. Malaria parasites, malaria density and absolute CD4 counts were carried out on all three groups. Participants with CD4 counts below 350 cells/mm<sup>3</sup> were considered immunocompromised and likely to develop opportunistic infections.</p><p><strong>Results: </strong>Most study participants were aged 21-40 years (65.2%). The mean CD4 counts of HIV-positive patients not on ART (300 ± 211 cells/mm<sup>3</sup>) and those on ART (354 cells/mm<sup>3</sup>) were significantly lower than among controls (834 cells/mm<sup>3</sup>) (<i>p</i> < 0.001). Malaria prevalence was not statistically different between the controls (44.5%), patients on ART (40.5%), and those not on ART (39.5%) (<i>p</i> = 0.562). Compared to 7% immunodeficiency among controls, 56% of patients on ART and 65.5% of those not on ART had a CD4 count < 350 cells/mm<sup>3</sup> (<i>p</i> < 0.001). The prevalence of malaria parasitaemia among immunodeficient individuals (42.4%) was similar to prevalence among those with CD4 counts > 350 cells/mm<sup>3</sup> (40.8%; <i>p</i> = 0.695).</p><p><strong>Conclusion: </strong>These findings suggest that malaria parasitaemia is not an opportunistic infection among HIV-positive individuals in Nigeria.</p>","PeriodicalId":45412,"journal":{"name":"African Journal of Laboratory Medicine","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2022-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9724119/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10371668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Practices and barriers to screening for hyperglycaemia in pregnancy among providers of antenatal care in Jos, Nigeria. 尼日利亚乔斯市产前保健提供者筛查妊娠期高血糖的做法和障碍
IF 1.1 Q3 Health Professions Pub Date : 2022-10-31 eCollection Date: 2022-01-01 DOI: 10.4102/ajlm.v11i1.1845
Lucius C Imoh, Abdulazis S Longwap, Favour E Haruna, Oghale J Asieba, Joy P Istifanus, Joy A Imoh, Mathilda E Banwat

Background: Screening for hyperglycaemia in pregnancy (HIP) is an important component of comprehensive antenatal care. Screening practices for HIP in Nigeria and factors that influence these practices are not well understood.

Objective: We examined the screening practices for HIP and their correlates among antenatal healthcare providers (AHPs).

Methods: This descriptive cross-sectional study of AHPs providing all levels of antenatal care was conducted between August 2019 and September 2019 in Jos, Nigeria. Eligible AHPs completed a semi-structured, self-administered questionnaire, and data were analysed for adherence to recommended screening practices such as World Health Organization, International Association of Diabetes and Pregnancy Study Groups and National Institute for Health and Care Excellence guidelines.

Results: Of the 128 respondents included in the analysis, 59 (46.1%) were male and 69 (53.9%) were female. The mean participant age was 35.7 years (standard deviation: ± 8.5 years). Most (68.0%) screened all pregnant women (universal screening) for gestational diabetes mellitus. Fasting blood glucose (77.0%) and random blood glucose (55.7%) were the most common tests used. Only 27 respondents (22.1%) screened using the 75 g oral glucose tolerance test, and most were doctors, AHPs in faith-based or government institutions, tertiary institutions and facilities with availability of automated glucose analysers (p < 0.05 for all).

Conclusion: Screening practices for HIP among the AHPs do not generally conform to best practices. Hence, there is an urgent need for implementation of universal guidelines and provision of regular updates and basic glucose measuring devices for AHPs at all healthcare levels.

背景:妊娠期高血糖筛查(HIP)是全面产前保健的重要组成部分。尼日利亚HIP筛查做法和影响这些做法的因素尚不清楚。目的:我们研究了产前保健提供者(AHPs)的HIP筛查实践及其相关性。方法:这项描述性横断面研究于2019年8月至2019年9月在尼日利亚乔斯对提供各级产前保健的ahp进行了研究。合格的ahp完成了一份半结构化的、自我管理的问卷,并分析了数据对世界卫生组织、国际糖尿病和妊娠研究小组协会和国家健康和护理卓越研究所指南等推荐筛查做法的依从性。结果:纳入分析的128名被调查者中,男性59人(46.1%),女性69人(53.9%)。参与者平均年龄为35.7岁(标准差:±8.5岁)。大多数(68.0%)对所有孕妇进行妊娠期糖尿病筛查(普遍筛查)。空腹血糖(77.0%)和随机血糖(55.7%)是最常用的检测方法。只有27名受访者(22.1%)使用75g口服葡萄糖耐量试验进行筛查,大多数是医生、宗教或政府机构、高等教育机构和拥有自动葡萄糖分析仪的机构的ahp (p < 0.05)。结论:在ahp中,HIP的筛查实践通常不符合最佳实践。因此,迫切需要实施通用指南,并为所有医疗保健水平的ahp提供定期更新和基本的葡萄糖测量设备。
{"title":"Practices and barriers to screening for hyperglycaemia in pregnancy among providers of antenatal care in Jos, Nigeria.","authors":"Lucius C Imoh,&nbsp;Abdulazis S Longwap,&nbsp;Favour E Haruna,&nbsp;Oghale J Asieba,&nbsp;Joy P Istifanus,&nbsp;Joy A Imoh,&nbsp;Mathilda E Banwat","doi":"10.4102/ajlm.v11i1.1845","DOIUrl":"https://doi.org/10.4102/ajlm.v11i1.1845","url":null,"abstract":"<p><strong>Background: </strong>Screening for hyperglycaemia in pregnancy (HIP) is an important component of comprehensive antenatal care. Screening practices for HIP in Nigeria and factors that influence these practices are not well understood.</p><p><strong>Objective: </strong>We examined the screening practices for HIP and their correlates among antenatal healthcare providers (AHPs).</p><p><strong>Methods: </strong>This descriptive cross-sectional study of AHPs providing all levels of antenatal care was conducted between August 2019 and September 2019 in Jos, Nigeria. Eligible AHPs completed a semi-structured, self-administered questionnaire, and data were analysed for adherence to recommended screening practices such as World Health Organization, International Association of Diabetes and Pregnancy Study Groups and National Institute for Health and Care Excellence guidelines.</p><p><strong>Results: </strong>Of the 128 respondents included in the analysis, 59 (46.1%) were male and 69 (53.9%) were female. The mean participant age was 35.7 years (standard deviation: ± 8.5 years). Most (68.0%) screened all pregnant women (universal screening) for gestational diabetes mellitus. Fasting blood glucose (77.0%) and random blood glucose (55.7%) were the most common tests used. Only 27 respondents (22.1%) screened using the 75 g oral glucose tolerance test, and most were doctors, AHPs in faith-based or government institutions, tertiary institutions and facilities with availability of automated glucose analysers (<i>p</i> < 0.05 for all).</p><p><strong>Conclusion: </strong>Screening practices for HIP among the AHPs do not generally conform to best practices. Hence, there is an urgent need for implementation of universal guidelines and provision of regular updates and basic glucose measuring devices for AHPs at all healthcare levels.</p>","PeriodicalId":45412,"journal":{"name":"African Journal of Laboratory Medicine","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2022-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9634787/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40666980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
African Journal of Laboratory Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1